Wikipedia
Safinamide
Safinamide ( INN; brand name Xadago, former developmental code name EMD-1195686) is a drug indicated for the treatment of Parkinson's disease with multiple methods of action. In 2007, a Phase III clinical trial was started. It was scheduled to run until 2011. The compound was originally discovered at Farmitalia-Carlo Erba, first published in 1998 and developed by Newron Pharmaceuticals, which sold the rights to Merck-Serono in 2006. In October 2011 Merck-Serono announced that they would give all rights to develop the compound back to Newron.
Potential additional uses might be restless legs syndrome (RLS) and epilepsy. They were being tested in Phase II trials in 2008, but no results are available.